Vancomycin in Very-Early Onset Inflammatory Bowel Disease-Dysbiosis: Fight Fire with Fire?

about

Vancomycin in Very-Early Onset Inflammatory Bowel Disease-Dysbiosis: Fight Fire with Fire?

Item

http://www.wikidata.org/entity/Q47686862

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Vancomycin in Very-Early Onset ...... sbiosis: Fight Fire with Fire?

@en

Vancomycin in Very-Early Onset ...... sbiosis: Fight Fire with Fire?

@nl

type

Item

label

Vancomycin in Very-Early Onset ...... sbiosis: Fight Fire with Fire?

@en

Vancomycin in Very-Early Onset ...... sbiosis: Fight Fire with Fire?

@nl

prefLabel

Vancomycin in Very-Early Onset ...... sbiosis: Fight Fire with Fire?

@en

Vancomycin in Very-Early Onset ...... sbiosis: Fight Fire with Fire?

@nl

P1476

Vancomycin in Very-Early Onset ...... sbiosis: Fight Fire with Fire?

@en

P2093

Luc Biedermann

http://www.w3.org/2001/XMLSchema#string

P2860

Antibiotic exposure and IBD development among children: a population-based cohort study

From stool transplants to next-generation microbiota therapeutics

Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis.

Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial.

Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis.

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management.

Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial.

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management.

Increased Intestinal Microbial Diversity Following Fecal Microbiota Transplant for Active Crohn's Disease.

Risk factors for systemic vancomycin exposure following administration of oral vancomycin for the treatment of Clostridium difficile infection.

P304

327-328

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1159/000477088

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28609775

http://www.w3.org/2001/XMLSchema#string

P921

Very early onset inflammatory bowel disease

inflammatory bowel diseases